Lupin, Zydus Partner to Co-Market Semaglutide Injection for Diabetes in India

Lupin Limited and Zydus Lifesciences Limited have entered into a licensing and supply agreement to co-market an innovative Semaglutide injection in India. The partnership aims to improve access to advanced treatments for diabetes and weight management.

Agreement Details

Under the agreement:

• Lupin will have semi-exclusive rights to co-market the product in India
• Lupin will sell it under the brand names Semanext® and Livarise®
• Zydus will continue marketing the same product under SEMAGLYN™, MASHEMA™ and ALTERME™

Lupin will also pay Zydus:

• An upfront licensing fee
• Additional milestone-based payments

Focus on Better Patient Access

The partnership combines:

• Lupin’s strong distribution network in India
• Zydus’ expertise in drug development

The goal is to make advanced therapies for diabetes and metabolic disorders more widely available across the country.

About the Semaglutide Injection

The product is a Semaglutide injection (15 mg/3 ml) delivered through a reusable pen device, designed for ease of use.

It is used for:

• Adults with type 2 diabetes
• Patients whose blood sugar is not well controlled through diet and exercise

This therapy is part of the GLP-1 class of drugs, which are increasingly used worldwide for diabetes and weight management.

Read More: Adani Enterprises Rights Issue: Second Call Payment Deadline Falls Today.

Management Commentary

Leaders from both companies highlighted that:

• The partnership strengthens their commitment to providing advanced treatment options.
• The new delivery device is designed to make treatment simpler and more convenient for patients.
• The collaboration will help expand reach and improve patient outcomes in India.

Lupin share price Movement

Lupin share price (NSE: LUPIN) was trading at ₹2,296.10 on March 17, 2026, around 1:23 PM, up 0.25% (₹5.70) for the day. The stock opened at ₹2,306.00, touched an intraday high of ₹2,312.20, and a low of ₹2,285.40. Its quarterly dividend stands at ₹2.98 per share. Over the past year, the stock has recorded a 52-week high of ₹2,377.60 and a 52-week low of ₹1,795.20.

Conclusion

The collaboration between Lupin and Zydus marks an important step in expanding access to modern diabetes treatments in India. By combining their strengths, both companies aim to make innovative therapies like Semaglutide more accessible, helping patients better manage diabetes and improve their quality of life.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.